The inability to demonstrate efficacy or presence of safety concerns are among the primary reasons why clinical trials fail¹.
Our TrueSignature® clinical biomarker panels help overcome these obstacles in drug development and offer a solution to reliably monitor biomarkers.
The panels offer versatile protein combination options, encompassing single proteins, multiplex panels of up to 50 proteins, and even hyperplex panels of up to 800 proteins. The panels can be customized for various therapeutic areas to best suit your research goals.
The TrueSignature platform is powered by Parallel Reaction Monitoring (PRM) and SureQuant mass spectrometry. These technologies allow for complete customization down to amino acid resolution (i.e. mutations, truncations, isoforms) and are not dependent on affinity-based recognition and reagent availability. You select the proteins; we analyze them for you.
TrueSignature panels can be developed within weeks and are available both as a standalone solution or an integrated solution, in which insights from TrueDiscovery® studies help guide the choice of peptides in the custom panel.
Resources
Deliverables
The results are presented and discussed with you in a dedicated conference call and delivered electronically in PDF and Excel format.
Executive Summary
Materials and Methods
(suitable for publication)Complete Data Matrix
a) Peptide and protein relative intensities for all study samples
b) Peptide and protein absolute quantities based on stable isotope standards (if applicable)
Data Interpretation
a) Differentially regulated proteins with regulation factor and p-value
b) Coefficient of variation analysis
c) Multivariate analysis (e.g., PCA)
d) Hierarchical clustering analysis
e) Custom analysis upon request
Sample types and depths
Our Clinical Biomarker Panels solution can be applied to virtually any kind of sample type with minimal sample input.
Project management
Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.
